Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature

Choi, Daniel K., MD, MS*; Pillay-Smiley, Natasha, DO; Marzec, Sarah, MD, MA; Wadhwani, Nitin R., MD§; DiPatri, Arthur J., MD; Tomita, Tadanori, MD; Lulla, Rishi R., MD

Journal of Pediatric Hematology/Oncology: November 2018 - Volume 40 - Issue 8 - p 616–619
doi: 10.1097/MPH.0000000000001092
Clinical and Laboratory Observations

We describe 2 cases of rapidly progressive primary central nervous system malignant melanoma, and summarize 18 previously reported cases of this extremely rare tumor in children. Both patients presented with focal neurologic symptoms, with no evidence of skin or other organ system involvement. One patient was treated with temozolomide and etoposide, whereas the other was treated with multiple surgical resections, radiation therapy, and a trial of ipilimumab. New molecularly targeted and immune-based therapies used in metastatic melanoma in adults are potential new treatment options, but their efficacy and safety in pediatric patients needs to be established.

*Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Illinois at Chicago College of Medicine

Department of Pediatrics, Division of Hematology/Oncology/Stem Cell Transplantation

§Department of Pathology, Division of Pediatric Pathology

Department of Neurological Surgery, Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL

Division of Oncology, Cincinnati Children’s Hospital, Cincinnati, OH

The authors declare no conflict of interest.

Reprints: Daniel K. Choi, MD, MS, Division of Pediatric Hematology/Oncology, University of Illinois at Chicago College of Medicine, 840 S Wood Street, M/C 856, Chicago, IL 60612 (e-mail: dkchoi@uic.edu).

Received May 31, 2017

Accepted October 8, 2017

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.